- This event has passed.
Flu Resurgence: What does this mean for our sector?
June 10, 2022 @ 11:00 am - 12:30 pm AEST
Event Navigation
As Australia opened up to the world, the question arose as to what kind of influenza season we will have in 2022.
Flu prevalence in Australia has been at “historically low levels” since April 2020. However, this could change dramatically and we are seeing that 2022 will be a flu season like no other.
Not only are the circumstances unique but we will be forced to deal with the potential of ‘flurona,’ where the concurrent existence of COVID-19 and influenza in our community presents new public health challenges.
You can join our speakers who will discuss key drivers for the 2022 flu season, potential economic impacts of the resurgence, and what it means for the sector and Australian biosecurity. The discussion will also examine key learnings from COVID-19 that can help with flu preparedness, and technologies that are available to help combat flu more effectively.
This BioForum, sponsored by the State Government of Victoria, is taking place on Friday 10 June online via Zoom webinar.
We will be joined by the following speakers:
• Professor Ian Barr, Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza
• Dr Jonathan Anderson, Executive Medical Director, International Regions, Seqirus
• Dr Felicia Pradera, General Manager, Health Security Systems Australia, Medical Countermeasures Program Leader
See speaker bios below:
Event details
Date: Friday 10 June 2022
Time (AEST): 11:00am – 12:30pm Presentations (online)
Live stream: A link to join the event will be shared 24 – 48 hours prior to the event
Online registration: This is a free event for BioMelbourne Network Members & Non Members
Unsure if your organisation is a member? Check our Member Directory
Sponsored by the State Government of Victoria
Dr Jonathan Anderson, Executive Medical Director, International Regions, Seqirus
Jonathan Anderson is currently the Executive Medical Director for Seqirus, part of CSL, covering Asia-Pacific and Europe. Seqirus are one of the leading global biotechnology companies for both seasonal and pandemic influenza prevention. Before joining industry in 2010, he was a GP with a special interest in Infectious Diseases in Melbourne. Academic interests included HIV treatment & prevention, Human Papilloma Virus, and the role of health economics in decision-making for population health. In 2006 he worked within the Victoria Department of Health and Human Services to help implement a workbook for pandemic preparedness for GPs that he designed. During the recent pandemic he volunteered as a GP in the COVID mass vaccination clinics at the Royal Exhibition Building and in Ballarat. He has co-authored 38 peer-reviewed and other publications and has a PhD in Medicine from UNSW and Masters of Public Health from Melbourne.
Professor Ian Barr, Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza
Professor Ian Barr is currently the Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza (one of 5 globally) based at the Doherty Institute in Melbourne, Australia which has operated since 1992. The Centre plays an active role in the regional surveillance of human influenza. Ian has over 35 years’ experience in Research and Development both with academic and commercial groups including over 21 years at the Centre and has authored or co-authored nearly 300 publications including over 250 peer reviewed journal articles, reviews and editorials on various aspects of influenza. He holds an Honorary Professorial position in the Department of Microbiology and Immunology at the University of Melbourne.
Dr Felicia Pradera, General Manager, Health Security Systems Australia, Medical Countermeasures Program Leader
Felicia Pradera is the General Manager for Health Security Systems Australia, as division of DMTC Ltd and is currently on secondment from the Defence Science and Technology Group (DSTG). At DSTG she leads the National Medical Countermeasures Initiative and is Australia’s Science and Technology lead to the international Medical Countermeasures Consortium. Dr Pradera is responsible for the collaborative development of new platform technology and sovereign industrial capability to support Defence and National Security requirements against chemical, biological and radiological threats, emerging infectious disease and pandemics. Felicia has expertise in academic research (immunology), preclinical & clinical trials, intellectual property and complex program management. She specializes in medical countermeasures and health security on behalf of the Government in addition to providing strategic advice and guidance. Felicia has BSc from Murdoch University, BSc (Hons) from Melbourne University, Dr.rer.naturwissenschaftern from the Technical University of Berlin, and a Masters of Intellectual Property Law from Monash University.
Related Events
